Steroid Diabetes in Patients With Kidney Disease

Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Dec 7, 2023

Keywords

ClinConnect Summary

The clinical trial titled "Steroid Diabetes in Patients With Kidney Disease" is investigating how to better identify and manage steroid diabetes in patients with kidney diseases, specifically nephrotic syndrome. Steroid diabetes can occur when patients take steroid medications, which are often necessary for treating their kidney issues. If not caught early, this condition can lead to serious health problems, affecting the body in ways that can be hard to reverse. The trial aims to closely monitor patients using glucocorticoids (a type of steroid) to prevent these complications.

To participate in this study, you must be an adult patient aged between 65 and 74 years or 27 to 93 years who is using glucocorticoids for certain kidney-related conditions. You should be starting on a daily dose of at least 10 mg of prednisolone, a common type of glucocorticoid. However, if you already have diabetes, cannot communicate effectively, or have recently used glucocorticoids, you would not be eligible for this trial. Participants can expect regular check-ups to monitor their blood sugar levels and receive care aimed at catching any signs of steroid diabetes early. This study is currently recruiting participants, and your involvement could help improve treatment for others with similar health issues in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus；
• • 2. Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone；
• Exclusion Criteria:
• • 1. Patients with diabetes；
• • 2. Those who are unable to communicate through language；
• • 3. Uremic patients；
• • 4. Unable to perform blood glucose monitoring and follow-up as required；
• • 5. Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone；
• • 6. Participated in other clinical studies。